Pricing Reforms Prompt Canadian Business Rethink
Roche Has Withdrawn Tecentriq From HTA Processes
Executive Summary
The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.
You may also be interested in...
COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
Canada To Rethink Controversial Pricing Rules
Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.
Canadian Drug Pricing Reforms Could Lead To Medicine Shortages
Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.